Deep-Dive Due Diligence AI Generated Report on Compass Therapeutics, Inc. Common Stock (CMPX)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
CMPX_OUT_1 [2025-03-31 17:35:41 -0400] 2067 Bytes | 551 tokens | Cum: 551 tkns (6.89% of 8k)
==========================================================================
Listen up, partner—it's 5:35:41 PM on Mon Mar 31, 2025 -0400, and I’m revved up about Compass Therapeutics (CMPX), climbing from 1.99 to 2.5. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!
Here's the first list of news for Compass Therapeutics:
C1 - Today 04:05PM - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
C2 - Mar-27-25 10:20AM - Is Compass Therapeutics (CMPX) The Hot Biotech Stock Under $5?
C3 - Mar-02-25 10:22AM - Why Compass Therapeutics, Inc. (CMPX) is Skyrocketing So Far in 2025
C4 - Feb-27-25 08:00AM - Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update
C5 - Jan-29-25 08:00AM - Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
C6 - Jan-08-25 08:00AM - Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
C7 - Dec-10-24 08:00AM - Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
C8 - Dec-02-24 08:00AM - Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Compass Therapeutics (CMPX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".
CMPX_IN_2 [2025-03-31 17:35:41 -0400] 2 Bytes | 2 tokens | Cum: 553 tkns (6.91% of 8k)
==========================================================================
C1
CMPX_OUT_3 [2025-03-31 17:35:43 -0400] 1098 Bytes | 335 tokens | Cum: 888 tkns (11.10% of 8k)
==========================================================================
Showing C1 (chunk 1 of 3): C1:
**Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer**
Date: Today 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052773/0/en/Compass-Therapeutics-to-Host-Webcast-Highlighting-Top-Line-Clinical-Data-from-the-Ongoing-Randomized-Phase-2-3-Study-Evaluating-Tovecimig-in-Patients-with-Biliary-Tract-Cancer.html
March 31, 2025 16:05 ET| Source:Compass TherapeuticsCompass Therapeutics
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
CMPX_IN_4 [2025-03-31 17:35:43 -0400] 3 Bytes | 2 tokens | Cum: 890 tkns (11.12% of 8k)
==========================================================================
NEX
CMPX_OUT_5 [2025-03-31 17:35:44 -0400] 1039 Bytes | 286 tokens | Cum: 1176 tkns (14.70% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A2 - 2025-03-31T20:14:23Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...
A3 - 2025-03-31T20:05:00Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...
A4 - 2025-03-31T20:20:44Z - Compass Therapeutics (CMPX) to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Ran...
A5 - 2025-03-31T20:16:23Z - Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
CMPX_IN_6 [2025-03-31 17:35:44 -0400] 2 Bytes | 2 tokens | Cum: 1178 tkns (14.72% of 8k)
==========================================================================
A1
CMPX_OUT_7 [2025-03-31 17:35:49 -0400] 1098 Bytes | 337 tokens | Cum: 1515 tkns (18.94% of 8k)
==========================================================================
Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adverum Biotechnologies (NASDAQ:ADVM)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44573149/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers bioAffinity Technologies BIAF stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. Nutex Health NUTX shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. Compass Therapeutics CMPX stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. Plus Therapeutics PSTV stock moved upwards by 17.7% to $1.13. The market value of their
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
CMPX_IN_8 [2025-03-31 17:35:49 -0400] 495 Bytes | 135 tokens | Cum: 1650 tkns (20.62% of 8k)
==========================================================================
This report highlights the movement of health care stocks in Monday's after-market session. bioAffinity Technologies (BIAF) saw a 198.8% increase to $0.78 with a market cap of $12.1 million following the release of their Q4 earnings. Nutex Health (NUTX) also saw an increase after the release of their Q4 earnings, with shares rising 51.02% to $70.3 and a market cap of $382.2 million. Compass Therapeutics (CMPX) and Plus Therapeutics (PSTV) also saw increases of 18.42% and 17.7% respectively.
CMPX_OUT_9 [2025-03-31 17:35:50 -0400] 829 Bytes | 253 tokens | Cum: 1903 tkns (23.79% of 8k)
==========================================================================
This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!
B1 - 2025-02-04T13:08:00Z - Top 3 High-Momentum Companies Analysts Are Still Bullish On
B2 - 2024-09-03T12:00:00Z - Compass Therapeutics to Participate in Upcoming Investor Events
B3 - 2024-08-26T11:00:00Z - Eliem Therapeutics Announces Additions to its Leadership Team
B4 - 2024-08-07T12:00:00Z - Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
B5 - 2024-05-30T12:00:00Z - Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
B6 - 2024-05-28T20:10:00Z - Compass Therapeutics Announces CEO Transition
Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
CMPX_IN_10 [2025-03-31 17:35:50 -0400] 2 Bytes | 2 tokens | Cum: 1905 tkns (23.81% of 8k)
==========================================================================
B1
CMPX_OUT_11 [2025-03-31 17:35:53 -0400] 657 Bytes | 172 tokens | Cum: 2077 tkns (25.96% of 8k)
==========================================================================
Showing B1 (chunk 1 of 1): B1:
**Top 3 High-Momentum Companies Analysts Are Still Bullish On**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/top-3-highmomentum-companies-analysts-are-still-bullish-on-200656960Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
CMPX_IN_12 [2025-03-31 17:35:53 -0400] 253 Bytes | 41 tokens | Cum: 2118 tkns (26.47% of 8k)
==========================================================================
The analysts remain optimistic about three companies despite their recent stock rallies. These companies are Compass Therapeutics, Amprius Technologies, and Allot Communications. They believe that these momentum stocks have substantial upside potential.
CMPX_OUT_13 [2025-03-31 17:35:54 -0400] 524 Bytes | 127 tokens | Cum: 2245 tkns (28.06% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
S1 - 2025-02-27 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper.
Unless otherwise stated or the context otherwise indicates, references to the Company , we , our , us or similar terms refer to Compass Therapeutics, Inc. together with its wholly-ow...
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
CMPX_IN_14 [2025-03-31 17:35:54 -0400] 2 Bytes | 2 tokens | Cum: 2247 tkns (28.09% of 8k)
==========================================================================
S1
CMPX_OUT_15 [2025-03-31 17:35:56 -0400] 1098 Bytes | 228 tokens | Cum: 2475 tkns (30.94% of 8k)
==========================================================================
Showing S1 (chunk 1 of 6): S1:
Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations.
Unless otherwise stated or the context otherwise indicates, references to the Company , we , our , us or similar terms refer to Compass Therapeutics, Inc. together with its wholly-owned subsidiaries, which we refer to as Compass Therapeutics.
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included in this Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading Special Note Regarding
--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)
CMPX_IN_16 [2025-03-31 17:35:56 -0400] 462 Bytes | 79 tokens | Cum: 2554 tkns (31.92% of 8k)
==========================================================================
This section describes the management's discussion and analysis of the financial condition and results of operations for Compass Therapeutics, Inc. and its wholly-owned subsidiaries. It urges the reader to go through the discussion along with the consolidated financial statements and related notes included in the Form 10-K. The section may contain forward-looking statements about the company's plans and strategy, which are subject to risks and uncertainties.
CMPX_OUT_17 [2025-03-31 17:36:06 -0400] 5585 Bytes | 1661 tokens | Cum: 4215 tkns (52.69% of 8k)
==========================================================================
This is our set of metrics.
Please analyze the numbers.
+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 1,565,810 | Perf Month: -34.48% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 1.53M | Perf Quarter: 25.00% | Short Float: 5.71% | ROE: -36.07% |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.02 | Index: RUT | Short Ratio: 3.00 | ROI: -37.54% |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 30.33 | Market Cap: 262.73M | Short Interest: 4.61M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.21 | Shs Outstand: 137.82M | Beta: 1.18 | EPS Surprise: -12.13% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -19.55% | Shs Float: 80.70M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -32.64% | Inst Own: 38.87% | Sales past 5Y: 0.00% | Earnings: Feb 27 BMO |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 5.85% | Insider Own: 41.64% | Employees: 35 | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -19.83% | Insider Trans: 0.00% | Debt/Eq: 0.05 | |
+--------------------+-----------------------+-------------------------+-----------------------+
The next section covers any insider trading.
If this section may be blank due to no recent filings.
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Boylan James P (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by GORDON CARL L (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Anderman Jonathan (Sr VP, Gen Counsel & Corp Sec) on 2025-02-11
- Stock Option (Right to Buy): 280000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Chiniara Ellen (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Ferneau Philip (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by GRAY MARY ANN (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Lerner Neil (SVP, CAO) on 2025-02-11
- Stock Option (Right to Buy): 200000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by LINDAHL RICHARD S (Unknown Title) on 2025-02-11
- Stock Option (Right to Buy): 40000 shares at $0 (D)
Inside Trans: Compass Therapeutics, Inc. (CMPX) by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2025-02-11
- Stock Option (Right to Buy): 1500000 shares at $0 (D)
[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -10481000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 1.9
Average Volume: 880135.71
30-Day High: 2.78
30-Day Low: 1.9
[Detailed Financials: Q3 2024]
- Total Assets: $149,151,000.0
- Total Liabilities: $10,753,000.0
- Total Equity: $138,398,000.0
- Current Assets: $141,140,000.0
- Current Liabilities: $4,433,000.0
[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.08
[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $17,965,000.0
[Detailed Financials: Q2 2024]
- Total Assets: $155,611,000.0
- Total Liabilities: $9,507,000.0
- Total Equity: $146,104,000.0
- Current Assets: $153,546,000.0
- Current Liabilities: $9,507,000.0
[Income Statement: Q2 2024]
- Revenue: $850,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1
[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-4,270,000.0
==== END OF FINANCIAL REPORT ====
You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.
Now, complete this report with the following:
1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE
CMPX_IN_18 [2025-03-31 17:36:06 -0400] 1075 Bytes | 221 tokens | Cum: 4436 tkns (55.45% of 8k)
==========================================================================
1) Brief Summary: The company has experienced a significant drop in performance over the last month with a decrease of -34.48%. However, the performance over the last quarter has increased by 25.00%. The company's volume is fairly stable, with a slight increase compared to the average volume. The company's debt to equity ratio is low, indicating that the company is not overly reliant on debt to finance its operations. The company has a negative return on equity and return on investment, which suggests that the company is not generating a profit. The company's sales and EPS have not been performing well. The high number of insider transactions suggest confidence from the company's key stakeholders.
2) MARKET_SCORE[52]: Given the company's recent performance and insider transactions, there is a 52% likelihood of an upward move.
3) PRICE_TARGET[$2.85]: Considering the company's recent performance, the high today could potentially be 50% higher than the current price.
4) AI_RPT_HEADLINE: "Despite Recent Slump, Insider Confidence Suggests Potential Turnaround".
CMPX_OUT_19 [2025-03-31 17:36:08 -0400] 676 Bytes | 167 tokens | Cum: 4603 tkns (57.54% of 8k)
==========================================================================
Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)
CMPX_IN_20 [2025-03-31 17:36:08 -0400] 94 Bytes | 28 tokens | Cum: 4631 tkns (57.89% of 8k)
==========================================================================
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
CMPX_IN_21 [2025-03-31 17:36:08 -0400] 126 Bytes | 29 tokens | Cum: 4660 tkns (58.25% of 8k)
==========================================================================
====================================
[2025-03-31 17:36:08] # Analysis Completed
Elapsed Time: 27.50 seconds